Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Net Income (2019 - 2025)

Historic Net Income for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$78.2 million.

  • Nurix Therapeutics' Net Income fell 3359.92% to -$78.2 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$264.5 million, marking a year-over-year decrease of 3662.16%. This contributed to the annual value of -$264.5 million for FY2025, which is 3662.16% down from last year.
  • According to the latest figures from Q4 2025, Nurix Therapeutics' Net Income is -$78.2 million, which was down 3359.92% from -$86.4 million recorded in Q3 2025.
  • Nurix Therapeutics' Net Income's 5-year high stood at -$24.3 million during Q1 2021, with a 5-year trough of -$86.4 million in Q3 2025.
  • Moreover, its 5-year median value for Net Income was -$43.0 million (2022), whereas its average is -$45.0 million.
  • Per our database at Business Quant, Nurix Therapeutics' Net Income tumbled by 44804.75% in 2021 and then skyrocketed by 4652.76% in 2023.
  • Over the past 5 years, Nurix Therapeutics' Net Income (Quarter) stood at -$37.7 million in 2021, then dropped by 23.95% to -$46.7 million in 2022, then increased by 10.19% to -$42.0 million in 2023, then plummeted by 39.55% to -$58.5 million in 2024, then crashed by 33.6% to -$78.2 million in 2025.
  • Its Net Income was -$78.2 million in Q4 2025, compared to -$86.4 million in Q3 2025 and -$43.5 million in Q2 2025.